{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'End of Study /', 'ITC', 'Assessment', 'Screening', 'Treatment Period', 'Follow-up (FU) Period', 'Early', 'Unscheduled', 'Period', 'Discontinuation', 'Visits Treatment', 'TC1V1', 'SCR', 'TC1V2', 'TC1V3', 'TC1V4', 'TC1V5', 'TC1V6', 'TC1V7', 'TC1V8', 'TC1V9', 'Cycle 1', '(SEB)', 'Trial Day (Visit', 'Day -14', '1', '8+1', '15+1', '22+1', '29+1', '36+1', '43=1', '501', '57+1', 'ITCnVn', 'EoS/ED', 'UNS\"', 'Window)', 'to 1', 'Visits Subsequent', 'TC nV3', 'TC nV5', 'TC nV6', 'TC NV7', 'TC nV9', 'Treatment Cycle(s)b', '(TCnB)', 'Trial Day (Visit', '(X+7)', '(X+14)', '(X+21)', '(X+28)', '(X+35)', '(X+42)', '(X+49)', '(X+56)', 'x', 'Y=2', '182+3', 'Window)', '1', '1', '1', '1', '1', '1', '1', '1', 'EoTY', 'Serum pregnancy test', 'X', 'Urine pregnancy test', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Anti-AChR/anti-MuSK', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'antibodies', 'Total IgG and its', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'subtypes\u00b0', 'Viral testsP', 'X', 'ADA9', 'X', 'X\u00b0', 'X\u00b0', 'X', 'X', 'X', 'Pharmacokinetics', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Administration of', 'X1', 'X', 'X', 'X', 'ARGX-113 or placebos', 'Prior*/concomitant/', 'X', 'rescue therapy', 'Adverse events', 'X', 'AChR = Acetylcholine Receptor; ADA = Anti-Drug Antibodies; ECG = Electrocardiogram; ED = Early Discontinuation; EoS = End of Study; EoT = End of Treatment; EQ-5D-5L = EuroQoL', '5 Dimensions 5 Levels; IgG = Immunoglobulin G; ITC(V) = Inter Treatment Cycle (Visit); MG-ADL = Myasthenia Gravis Activities of Daily Living; MGC = Myasthenia Gravis Composite;', 'MG-QoL15r = 15-item Quality of Life scale for Myasthenia Gravis [Revised version]; MuSK: Muscle-Specific Kinase; QMG = Quantitative Myasthenia Gravis; SCR = Screening; SEB = Study', 'Entry Baseline; TCB = Treatment Cycle Baseline; TCV = Treatment Cycle Visit; UNS = Unscheduled; V = Visit.', 'a', \"The Inter Treatment Cycle (ITC) period consists of visits every 2 weeks, starting 14 days ( 2 days) from the last visit of the previous Treatment Cycle. The visit denominator ('n') will start\", 'at 1 at each period. At each ITCnV, an evaluation of the need for re-treatment should be done prior to decide whether assessments listed for ITCnV or TCnV1 are to be performed.', 'b', 'Last Treatment Cycle in the trial should not start later than on Day 127 of the trial. If the patient is in need of re-treatment after this date, the patient should have the EoS/ED visit performed', 'and, if eligible, he/she can roll-over into the long-term, single-arm, open-label follow-on ARGX-113-1705 trial.', 'c', 'No trial-related assessment is to be carried out before the patient has signed the informed consent form (ICF).', 'argenx BVBA', 'Confidential', 'Page 29 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'd', 'Randomization (at the first Treatment Cycle Baseline [TC1B] only) should be performed as soon as possible after Screening with approximately 2 weeks, however only after confirmation of', 'eligibility of the patient.', 'Efficacy and quality of life assessments should be completed pre-dose on each dosing day and should be performed prior to any other trial-specific assessment, except for obtaining informed', 'consent at Screening and the weight assessment, if applicable. The MG-ADL scale needs to be performed prior to all other efficacy or quality of life assessments. Acetylcholinesterase', '(AChE) inhibitors must be halted for at least 12 hours before the QMG assessment (consistent with the revised manual for the QMG test as recommended by the Myasthenia Gravis', 'Foundation of America Inc [MGFA]). A total MG-ADL score > 5 with more than 50% of this total score attributed to non-ocular symptoms should be met at Screening and Baseline (TCnB).', 'f', 'Suicidal ideation and behavior will be assessed pre-dose on dosing days via a targeted question based on the Patient Health Questionnaire item 9 (PHQ-9) (Simon, Rutter et al. 2013).', 'g', 'The physical examination will be performed pre-dose on dosing days. See Section 7.2.3 for an overview of the different assessments.', 'h', 'Height will be measured at Screening only and weight will be measured at Screening, at the EoS/ED visit, and when there is an obvious weight change compared to the last weight', 'assessment.', 'i', 'Vital signs (supine blood pressure, heart rate, body temperature) will be performed pre-dose on dosing days. It is recommended that the method used to measure body temperature at', 'Screening is maintained throughout the trial for each patient.', 'j', 'ECG will be performed pre-dose on dosing days.', 'k', 'Samples for clinical laboratory tests (hematology, clinical chemistry and FSH, if applicable) will be collected pre-dose on dosing days (see Appendix 6). In addition, total IgG at Screening is', 'to be assessed for defining eligibility. Patients need to be fasted at least 8 hours prior to each sampling.', '1', 'Urine samples will be collected pre-dose on dosing days (see Appendix 6).', 'm', 'A serum pregnancy test will be performed on the samples taken for clinical laboratory tests (only for women of childbearing potential, see DEFINITION OF TERMS).', 'n', 'A urine pregnancy test will be performed on the urine samples taken for urinalysis (pre-dose on dosing days) (only for women of childbearing potential, see DEFINITION OF TERMS).', 'o', 'Samples for pharmacodynamic (PD) biomarkers will be collected pre-dose on dosing days (see Appendix 6). Anti-AChR antibodies will be measured in AChR-Ab seropositive patients', 'only. Anti-MuSK antibodies will be measured in MuSK-Ab seropositive patients only.', 'p', 'Viral tests will be performed on samples taken at Screening (see Appendix 6).', 'q', 'Samples for anti-drug antibodies (ADAs) will be collected pre-dose if sampling is to be performed on dosing days. During the first Treatment Cycle, samples for ADA will be taken at Visits', '1, 4, 6 and 9. As from the second Treatment Cycle onwards, samples for ADA will only be taken at Visits 1 and 9 of the corresponding Treatment Cycle and EoS/ED.', 'r', 'Pharmacokinetic (PK) samples will be collected at Visits 1, 2, 3, 4, 5, and 6 and EoS/ED. On dosing days, PK samples will be collected pre-dose (within 1 hour prior to start of infusion) and', 'after the end of each infusion (within 1 hour after end of infusion).', 'The Investigational Medicinal Product (IMP; ARGX-113 or placebo) will be administered as an intravenous (IV) infusion over a period of 1 hour at Visits 1, 2, 3, and 4. Patients will remain', \"at the site for at least 1 hour following the end of the infusion for safety monitoring based on the patient's clinical status.\", 'At TCnV1, the conditions for re-treatment will be checked before administration of the IMP.', 'An unscheduled (UNS) visit can be on request of the patient or the Investigator. During the UNS visit, additional assessments as indicated in the SoA can be performed at the discretion of', 'the Investigator, depending on the reason for the UNS visit.', 'For patients who discontinue early from randomized treatment, the assessments will depend on the visit at which it was decided that the patient had to discontinue early from randomized', 'treatment (see Section 5.6). Patients who discontinue early from randomized treatment within a Treatment Cycle will have to complete the EoT assessments and complete the remaining', 'visits in the current Treatment Cycle prior to entering the Safety and Disease Severity Follow-up (FU) period as per the SoA for Patients who Discontinued Early from Randomized', 'Treatment (Table 2). These patients will not receive any further IMP administration during the trial. Patients who discontinue early from randomized treatment in the ITC period will have to', 'complete the EoT assessments and then continue into the Safety and Disease Severity Follow-up period as per Table 2.', 'W', 'Clinically relevant prior treatment will only be recorded once at Screening.', 'argenx BVBA', 'Confidential', 'Page 30 of 110']\n\n###\n\n", "completion": "END"}